European Archives - Page 717 of 1114 - European Medical Journal

The European Medical Journal Presents: EMJ Hematology 2019

Detailing some of the most important topics in haematology, EMJ Hematology 7.1 is now available.

Cell therapy takeover

Over the past year investigation into cell therapies has grown markedly, with an estimated 80% increase; the US and China are taking the lead in the development of these therapies, with Europe the closest behind.

Tagraxofusp is a Novel Targeted Therapy Directed to CD123

Blastic plasmocytoid dendritic cell neoplasm (BPDCN), a rare, highly aggressive haematologic malignancy, often with cutaneous and other extramedullary…

Review of the European Hematology Association (EHA) Congress 2019

EHA President Pieter Sonnevel welcomed the 12,614 haematology professionals to the Dutch capital, the largest number of attendees recorded…

EMJ Hematology 7.1 2019

EMJ Hematology 7.1 aims to provide you with a detailed review of the event, an account that is perfectly accompanied by a hand-picked selection of…

Rebooting the Myeloma Treatment Programme

Treatment of MM requires a multifaceted approach using a combination of therapies targeting the several pathophysiological pathways involved in the…

Post-Transplant Cyclophosphamide in HLA Matched and Haploidentical Transplant Recipients Receiving Myeloablative Timed Sequential Busulfan Conditioning Regimen: Results of a Phase II Study

The authors report a prospective Phase II trial to assess (a) if post-transplant cyclophosphamide (PTCy) could be safely incorporated in a timed…

EHA 2019 Interviews

Find out more about about the EHA Congress through our interviews with members of the various committees required to help…

Umbilical Cord Blood Donation: An Evolving Lifeline for the Stem Cell Field

Cord blood can be collected and stored from the placenta and umbilical cord following the birth of a new-born. It is replete with haematopoietic stem…

Autologous Dendritic Cell Vaccination to Prevent Progression and Relapse in Multiple Myeloma

Data from the National Cancer Institute showed that 50% of myeloma patients survive past 5 years post-diagnosis. This is encouraging but also warns…